A long-awaited cancer treatment reaches patients.

TUMOR-infiltrating immune cells; PATENT offices; IMMUNE system; IMMUNOLOGISTS; PHYSICIANS; T cells

A recent breakthrough in cancer treatment involves using the body's immune system to fight against cancer. The U.S. Food and Drug Administration has approved the first T cell therapy for a solid tumor, called Amtagvi, which involves removing T cells from a patient's tumor and growing them in the lab before injecting them back into the patient. This therapy, known as TIL therapy, has been in development since the late 1960s and builds on ancient reports of cancer going into remission after an infection. While TIL therapy is currently approved for advanced melanoma, studies suggest it may also be effective against other types of solid tumors. However, there are still many unanswered questions about how the immune system fights cancer and why therapies work for some patients but not others. [Extracted from the article]

Copyright of Science News is the property of Society for Science & the Public and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)